why choose us

First received: April 20, 2023

Clinical Trial: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

Study Status: Completed

Recruit Status: RECRUITING

Condition: Urothelial Carcinoma Bladder

Study Type: INTERVENTIONAL


Official Title: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (TASUC-Neo): A Pilot Study of Degarelix in Combination With Neoadjuvant Gemcitabine and Cisplatin in Muscle-Invasive Urothelial

Brief Summary: This study is for patients who have bladder cancer that invades into the muscle wall of the bladder.The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to remove the bladder (cystectomy).In this study, the investigators will test participants' bladder cancer to see if their bladder cancer has a receptor for testosterone inside the bladder cancer cells.If it has the testosterone receptor…

Read more